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Enterovirus 75 and
Aseptic Meningitis,
Spain, 2005
To the Editor: Although most
human enterovirus (EV) (genus
Enterovirus, family Picornaviridae)
infections are asymptomatic, they can
cause upper respiratory illness, febrile
rash, aseptic meningitis, pleurodynia,
encephalitis, acute flaccid paralysis,
and neonatal sepsislike disease (1).
Most EVs have been implicated in
aseptic meningitis, most notably
echovirus (E) 30, 9, 6, and 11 and
coxsackie B virus (CBV) type 5 (2);
other serotypes are less frequently
associated with neurologic disease.
New EV serotypes have come to
light, chiefly as a result of molecular
typing methods (3–6). EV75 was pro-
posed as a new serotype of the EV
genus in 2004 (5). Retrospective
analysis showed that it had circulated
sporadically in Asia, the United
States, and Africa since at least 1974.
Only 8 isolates of this serotype have
been reported worldwide, in 1974,
1985, 1986, 1987 (n = 2), 1998, and
2000 (n = 2). Infection in those cases
was associated with respiratory dis-
ease, acute flaccid paralysis, neonatal
jaundice, failure to thrive, or unspeci-
fied neurologic disease or was asymp-
tomatic. At the time of writing this
manuscript, EV75 had not been linked
to aseptic meningitis.
From May 2005 through January
2006, 106 EVs were received for typ-
ing from Spanish hospital laborato-
ries; 46 of them were from patients
with aseptic meningitis, 10 from
patients or contacts of patients with
acute flaccid paralysis, 27 from
patients with fever, 7 from patients
with respiratory diseases, and 16 from
other patients. Twenty EVs could not
be typed by serum neutralization (7);
however, 3′ terminus VP1 gene
sequence analysis (8) showed that
they were E18 (n = 7), CBV3 (n = 1),
and E16 (n = 2); 2 could not be typed
with serologic or molecular methods
because the 3′ terminus of VP1 gene
amplification was negative. The
analysis of the 3′ terminus of VP1
gene of the remaining 5 cerebrospinal
fluid (CSF) and 3 nasopharyngeal iso-
lates showed that they were similar to
the recently proposed EV75 serotype
(5). These 8 isolates were obtained
from samples from children in Bilbao
(n = 3), Granada (n = 3), Barcelona (n
= 1), and the Canary Islands (n = 1).
In 4 patients with aseptic meningitis,
EV75 was isolated from CSF. EV75
was isolated from CSF of a fifth
patient who had symptoms of fever
and irritability. The remaining 3 EV75
isolates were from nasopharyngeal
swabs of children who had fever, res-
piratory disease, or gastroenteritis. All
isolates were grown in cell lines
(rhabdomyosarcoma, lung adenocar-
cinoma, and human fetal lung fibrob-
last) and identified as EV by immuno-
fluorescence with pan-EV antibody
assays (Pan Entero Blend Chemicon,
Temecula, CA, USA, and Monoclonal
Mouse Anti-Enterovirus, Dako,
Glostrup, Denmark).
Phylogenetic analysis of the iso-
lates from 2005 was performed on the
basis of complete VP1 gene sequence
(GenBank accession nos. DQ468137–
DQ468142). The 5′ terminal domain
was obtained by reverse transcrip-
tase–PCR with specific primers
EV75_sense: 5′-GAAAGCTTYTTC-
CAAGGGGA-3′ and EV75_anti: 5′-
GAGAAGTGKGACCAWCCATC-
3′. Phylogenetic analysis of the
Spanish isolates and representatives
of all other species B EVs showed that
the Spanish isolates clustered (boot-
strap value 100, Figure) with strains
USA/OK85-10362, ETH74-1341,
USA/VA86-10363, USA/CT87-
10364-5, OMA98-10366, and
BAN00-10367-8 (accession nos.
AY556063–AY556070), correspon-
ding to the proposed EV75. The
Spanish isolates constitute a subgroup
(bootstrap value 100, Figure). The
similarity between the Spanish cluster
and other EV75 isolates was
82.8%–85.4% at the nucleic acid
level. Although the entire VP1
sequence was not available for the
isolates from 2006, the VP1 3′ termi-
nal analysis showed the strains
belonged to the same cluster.
To our knowledge, this is the first
isolation of EV75 in Spain. Indeed,
isolation of EV75 has not been report-
ed in Europe. Given that the European
EV75 isolate grows easily in a variety
of cell lines, is detected by common
EV genus-specific antibodies, and that
EV surveillance and typing were per-
formed in Spain since 1988 (2), EV75
might have begun to circulate in Spain
recently. However, because isolates
are not obtained from all aseptic
meningitis patients and many EVs are
detected by PCR but never typed, we
cannot rule out the possibility of previ-
ous asymptomatic circulation.
The European strains of EV75
appear to represent a different evolu-
tionary lineage than those previouslyLETTERS
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described in the United States, Asia,
and Africa (9). Only 1 of those EV75s
was obtained from CSF (a nonspecif-
ic neurologic syndrome). Thus, EV75
has not been associated with aseptic
meningitis, despite the fact that EV
infections are a common cause of
aseptic meningitis. Most of the
Spanish isolates (5 of 8) were associ-
ated with aseptic meningitis in chil-
dren. Although the number of EV75-
associated cases was not high (as a
percentage of the number of EVs iso-
lated from aseptic meningitis patients,
10.8%), the wide distribution of the
cases may indicate wide circulation.
To avoid outbreaks of aseptic menin-
gitis caused by previously noncircu-
lating EVs (EV13, 2001 [10]) and to
help define the extent of circulation of
newly identified EV types, careful
surveillance of aseptic meningitis
should be undertaken.
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Ciprofloxacin-
resistant
Salmonella
Kentucky in
Travelers
To the Editor: Ciprofloxacin is
the treatment of choice of severe non-
typhoidal  Salmonella infections in
adults. Resistance to ciprofloxacin has
been found exceptionally in nonty-
phoidal  Salmonella enterica isolates
and only in serotypes Typhimurium,
Choleraesuis, and Schwarzengrund
(1–8). Such isolates have been col-
lected from humans and animals in
Europe, Asia, and North America.
We report the emergence of
ciprofloxacin-resistant isolates of S.
Kentucky since 2002 in French travel-
ers returning from northeast and east-
ern Africa. From 2000 through 2005,
197  S.  Kentucky isolates from
humans (1 per patient) were
serotyped, from 69,759 total S. enter-
ica isolates serotyped at the French
National Reference Centre for
Salmonella. Antimicrobial drug sus-
ceptibility was determined for 186
isolates by the disk-diffusion method
with 32 antimicrobial drugs, as previ-
ously described (9). Resistance to sev-
eral drugs, amoxicillin (18%), gen-
tamicin (16%), nalidixic acid (21%),
sulfonamides (24%), and tetracycline
(24%), has been observed from 2000
through 2005.
A total of 17 (9%) ciprofloxacin-
resistant S. Kentucky strains were iso-
lated. Aresistant isolate that was unty-
pable by conventional serotyping
(rough) but that had a pulsed-field gel
electrophoresis (PFGE) profile asso-
ciated with serotype Kentucky, was
included in this study. Ciprofloxacin
MIC levels in these isolates, deter-
mined by standard agar doubling dilu-
tion as previously described (2), were
4–16 mg/L. The first ciprofloxacin-
resistant strain was isolated in
December 2002 from a French tourist
who had gastroenteritis during a Nile
cruise in Egypt. In 2004 and 2005, 17
ciprofloxacin-resistant isolates were
identified in unrelated adults who
lived in different cities of France at
different times of the year. The 16
patients we contacted acquired the
infection during or immediately after
travel to Egypt (10 patients), Kenya
and Tanzania (3), or Sudan (1). In 2
cases, gastroenteritis occurred 2
months after travel to Egypt. None of
the investigated cases were fatal or
life-threatening.
The 18 ciprofloxacin-resistant iso-
lates (17 serotype Kentucky and 1
rough) displayed various susceptibili-
ty patterns, from single resistance to
quinolones to multiple resistance (up
to 9 antimicrobial agents). To identify
mutations responsible for cipro-
floxacin resistance, the quinolone
resistance–determining regions
(QRDRs) of gyrA,  gyrB,  parC, and
parE were amplified by PCR and
sequenced as described previously
(3,9), except that different forward
primers for gyrB (5′-TTATCGACGC-
CGCGCGTGCGC-3′) and parE (5′-
CGCGTAACTGCATCG-GGTTC-3′)
were used. The 18 ciprofloxacin-
resistant isolates had different double
mutations in gyrA leading to amino
acid substitutions, Ser83Phe and
Asp87Gly (8 isolates), Ser83Phe and
Asp87Asn (5), and Ser83Phe and
Asp87Tyr (5), but had identical muta-
tions in parC (resulting in Ser80Ile).
An additional substitution was
observed in ParC, Thr57Ser. This sub-
stitution, however, did not appear to
be associated with quinolone resist-
ance because it was also identified in
nalidixic acid–susceptible isolates.
No isolates had substitutions in the
QRDRs of GyrB and ParE. All iso-
lates tested by PCR for the plasmid-
mediated quinolone resistance–con-
ferring gene qnrA (9) were negative.
In the presence of the efflux pump
inhibitor Phe-Arg-β-naphthylamide,
the MICs of ciprofloxacin were
reduced from 4-fold to 16-fold, which
suggests that an active efflux mecha-
nism was present (2). The involve-
ment of the AcrAB-TolC efflux sys-
tem was determined by measuring
AcrAexpression with a method previ-
ously described (5). A moderate pro-
duction of AcrA (3- to 4-fold increase
when compared with the baseline pro-
duction of AcrA in reference strain
98K) was observed in all but 1
ciprofloxacin-resistant isolate. This
isolate overproduced (6-fold) AcrA,
which correlated with a higher
ciprofloxacin MIC (16 mg/L).
The 18 ciprofloxacin-resistant iso-
lates and 14 ciprofloxacin-susceptible
S. Kentucky isolates used for compar-
ison were genotyped by PFGE with
XbaI restriction and PulseNet’s run-
ning conditions, as described previ-
ously (9). Each profile that differed by
>1 clear band >50 kb was considered a
distinct profile. The 18 resistant iso-
lates displayed 9 profiles that differed
by 1 to 3 bands (Dice correlation coef-
ficient 55%) (Figure). Profile X1c was
predominant (7 [39%] of 18). The 6
pansusceptible isolates tested dis-
played 5 different patterns unrelated to
those of resistant isolates. Use of a